Market Overview

Relapsing Multiple Sclerosis (RMS) Pipeline Insight, 2018 Report - ResearchAndMarkets.com

Share:

The "Relapsing
Multiple Sclerosis (RMS) - Pipeline Insight, 2018"
drug
pipelines has been added to ResearchAndMarkets.com's
offering.

'Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2018' report
offers comprehensive Insight of the pipeline (under development)
therapeutics scenario and growth prospects across Relapsing Multiple
Sclerosis (RMS) development. The report provides detailed coverage of
the pipeline landscape for this mechanism of action, equipped with data
from multiple sources with complete pipeline analysis by developmental
stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the report:

  • The report provides a snapshot of the pipeline development for the
    Relapsing Multiple Sclerosis (RMS)
  • The report covers pipeline activity across the complete product
    development cycle, i.e. clinical, pre-clinical and discovery stages
    for the Relapsing Multiple Sclerosis (RMS)
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Relapsing Multiple Sclerosis (RMS)
  • The report also covers the dormant and discontinued pipeline projects
    related to the Relapsing Multiple Sclerosis (RMS)

Key Topics Covered:

1. Report Introduction

2. Relapsing Multiple Sclerosis (RMS) Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

  • AbbVie Inc.
  • Actelion Ltd
  • BIOCAD
  • Cognosci
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Merck KGaA
  • Pfenex Inc.
  • Receptos
  • VivaCell Biotechnology Espana S.L.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3w55ng/relapsing?w=4

View Comments and Join the Discussion!